Innovative Gene Therapy Lowers Eye Pressure in Mice as a Reversible Alternative to Glaucoma Drops
A groundbreaking gene therapy using CRISPR-Cas13d effectively reduces eye pressure in mice, providing a reversible and potentially less invasive alternative to daily glaucoma eye drops.
Recent advances in gene editing have demonstrated promising results in managing intraocular pressure (IOP), a key factor in glaucoma development. Researchers utilized the CRISPR-based effectors, specifically Cas13d, to target and downregulate two genes—AQP1 and CA2—that are integral to aqueous humor production within the ciliary bodies of mouse eyes. This innovative approach led to a significant reduction in eye pressure: treated mice experienced a decrease of approximately 2.5 mmHg and 1.7 mmHg in IOP, compared to control groups. Importantly, this method does not permanently alter the DNA, making it a reversible and adjustable treatment option. The study, published in PNAS Nexus, indicates that such gene therapy could be adapted for human use, requiring only monthly or less frequent administrations. While further research is necessary to optimize timing, dosage, and delivery methods, this technique offers a potential paradigm shift in glaucoma management, reducing reliance on daily eye drops that can cause adverse effects and are often poorly adhered to by patients.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Presence of Threadworm in the U.S. Indicates Revival of Forgotten Diseases
New research highlights the surprising resurgence of threadworm infections in South Carolina, indicating that neglected parasitic diseases are making a concerning comeback in the United States.
Medical Students Address Cancer Care Gaps in Rural British Columbia
University of British Columbia medical students are pioneering improvements in cancer survivorship care in rural BC, developing strategies to support primary care providers and enhance patient outcomes.
Clinical Trial Finds No Advantage of Unproven Stroke Treatment Over Placebo
A recent clinical trial reveals that perispinal etanercept, an unproven stroke treatment, is no more effective than placebo. The study highlights the importance of evidence-based medicine in stroke care.